Eli Lilly has reduced the price of its weight-loss drug Zepbound for patients paying out of pocket, while also introducing new single-use vial doses with lower costs. The company lowered the monthly prices of the 2.5-mg and 5-mg doses from $399 and $549 to $349 and $499, respectively. A new “Zepbound Self Pay Journey Program” allows patients to access savings directly through LillyDirect Self Pay Pharmacy Solutions, removing third-party supply chain entities.
The price adjustments come after Eli Lilly reported fourth-quarter sales of Zepbound that missed analysts’ expectations. The company has also seen shares rise by over 17% in the past year due to its weight-loss drug Mounjaro’s performance.
Source: https://www.investopedia.com/eli-lilly-cuts-price-of-weight-loss-drug-zepbound-for-self-pay-patients-11685911